Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 17/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 17/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 15/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797329 | 0.90 | GABRP (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL17112610 | 0.90 | GABRP (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL14968800 | 0.87 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL26129000 | 0.87 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL25372135 | 0.85 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2186724 | 0.85 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL25391666 | 0.85 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL5773702 | 0.85 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2719300 | 0.83 | GABRP (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3792324 | 0.83 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104684915-A | New bicyclic derivatives | HOFFMANN LA ROCHE | 2015-06-03 | — | — | CN | claimed |
| CN-116981670-A | Polycyclic compound containing nitrogen heterocycle, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-111793077-B | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 东莞市东阳光新药研发有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022194122-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-113549063-A | Preparation method of optically isomeric octahydro-2H-pyrrolo [3,4-c ] pyridine-2-carboxylic acid tert-butyl ester | 南京药石科技股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3590940-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-09 | — | — | EP | disclosed |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| CN-111793077-A | PD-1/PD-L1 small-molecule inhibitor and application thereof in medicines | 东莞市东阳光新药研发有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2900669-A1 | NEW BICYCLIC DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| CN-104684915-A | New bicyclic derivatives | HOFFMANN LA ROCHE | 2015-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | CHRNB2 2107/4885CHRNB4 1950/4885CHRNA3 1726/4885 |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | CHRNB2 2243/4885CHRNB4 2271/4885CHRNA3 1792/4885 |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | CHRNB2 2243/4885CHRNB4 2271/4885CHRNA3 1792/4885 |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | CHRNB2 2243/4885CHRNB4 2271/4885CHRNA3 1792/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | CHRNB2 2107/4885CHRNB4 1950/4885CHRNA3 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.